Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues
Research and collaboration revenue	$ 111	$ 0	$ 640	$ 194
Operating expenses
Research and development	18,470	9,832	35,680	17,677
General and administrative	7,494	2,494	13,282	4,568
Total operating expenses	25,964	12,326	48,962	22,245
Loss from operations	(25,853)	(12,326)	(48,322)	(22,051)
Other income (expense), net:
Interest income, net	6,943	771	12,487	1,817
Other (expense) income, net:	8	(58)	(1)	(50)
Total other income (expense), net	6,951	713	12,486	1,767
Net loss and comprehensive loss	(18,902)	(11,613)	(35,836)	(20,284)
Cumulative redeemable convertible preferred stock dividends	0	(3,776)	0	(7,510)
Net loss attributable to common stockholders	$ (18,902)	$ (15,389)	$ (35,836)	$ (27,794)
Net loss per share , basic	$ (0.28)	$ (3.93)	$ (0.63)	$ (7.15)
Net loss per share , diluted	$ (0.28)	$ (3.93)	$ (0.63)	$ (7.15)
Weighted average shares of common stock outstanding, basic	66,649,443	3,918,509	56,857,104	3,885,713
Weighted average shares of common stock outstanding, diluted	66,649,443	3,918,509	56,857,104	3,885,713